Ocugen Inc. (OCGN)
NASDAQ: OCGNHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
OCGN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $339.11M
- EPS (TTM)
- -$0.26
- Dividend yield
- None
- 52-week range
- 0.97 – 2.73
- Day range
- 1.00 – 1.05
- Volume / Avg
- 5.20M / 5.82M
- Beta
- —
- Shares outstanding
- 339.11M
- Next earnings
- Nov 4, 2026
52-week range
OCGN stock today
Shares of Ocugen (OCGN) finished lower on Oct 7 at $1.00, a drop of 3.85% or $0.04 per share, versus the S&P 500's 0.22% decline. Shares are 63.3% below their 52-week high of $2.73, set on Mar 17, 2026 and 3.1% above the 52-week low of $0.97, near the bottom of the past year's range. OCGN is down 25.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 43.2%.
Ocugen has posted a net loss over the last twelve months (EPS of -$0.26), so its P/E ratio is not meaningful. Ocugen's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Ocugen
Company profileOcugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Shankar Musunuri M.B.A., Ph.D.
- Headquarters
- Malvern, PA
- Employees
- 116
- IPO year
- 2014
- Website
- ocugen.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$12.17+1117.00%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.06
Ocugen peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| OBIOOrchestra BioMed Holdings Inc. | 5.66 | -3.08% | $340.19M | vs OCGN |
| AGENAgenus Inc. | 7.57 | +1.07% | $341.88M | vs OCGN |
| ARTVArtiva Biotherapeutics Inc. | 7.00 | -3.71% | $342.23M | vs OCGN |
| CABACabaletta Bio Inc. | 1.97 | -2.48% | $334.00M | vs OCGN |
| SCTXScribe Therapeutics Inc. | 17.57 | +7.59% | $332.63M | vs OCGN |
| RLMDRelmada Therapeutics Inc. | 3.25 | -0.91% | $346.68M | vs OCGN |
| CCCCC4 Therapeutics Inc. | 2.82 | -2.08% | $346.93M | vs OCGN |
| ENTAEnanta Pharmaceuticals Inc. | 12.37 | +1.64% | $360.28M | vs OCGN |
Indexes, lists and sector
Appears in lists
Ocugen stock FAQ
What is Ocugen's stock price today?
OCGN last traded at $1.00 as of Oct 7, 4:00 PM EDT, down 3.85% on the day. Prices are delayed at least 15 minutes.
Does Ocugen pay a dividend?
No. Ocugen does not currently pay a regular cash dividend.
When is Ocugen's next earnings date?
Ocugen is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.06.
Who is Ocugen's CEO?
Dr. Shankar Musunuri M.B.A., Ph.D. is the chief executive officer of Ocugen Inc., which has about 116 employees.
Has OCGN ever split its stock?
Yes. The most recent OCGN stock split was a 1-for-60 split on Sep 30, 2019.
What is the OCGN 52-week high?
The 52-week high for OCGN is $2.73 and the 52-week low is $0.97. The stock is currently 63.3% below its high.